China SXT Pharmaceuticals, Inc.
SXTC
$2.29
$0.7144.94%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | -112.17% | 0.00% | 168.04% | 0.00% |
| Total Depreciation and Amortization | 0.00% | -31.67% | 0.00% | -2.33% | 0.00% |
| Total Amortization of Deferred Charges | 0.00% | 10.50% | 0.00% | -62.41% | 0.00% |
| Total Other Non-Cash Items | 0.00% | 100.47% | 0.00% | -187.56% | 0.00% |
| Change in Net Operating Assets | 0.00% | -7.03% | 0.00% | -320.84% | 0.00% |
| Cash from Operations | 0.00% | -0.65% | 0.00% | -132.64% | 0.00% |
| Capital Expenditure | -- | -- | 0.00% | -- | -- |
| Sale of Property, Plant, and Equipment | 0.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00% | -29.59% | 0.00% |
| Cash from Investing | 0.00% | 497.06% | 0.00% | -65.31% | 0.00% |
| Total Debt Issued | 0.00% | 437.96% | 0.00% | 999.68% | 0.00% |
| Total Debt Repaid | 0.00% | -113.60% | 0.00% | 112.54% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 38.77% | 0.00% | -- | -- |
| Cash from Financing | 0.00% | 293.88% | 0.00% | 141.18% | 0.00% |
| Foreign Exchange rate Adjustments | 0.00% | 341.68% | 0.00% | 113.22% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | 951.23% | 0.00% | 110.37% | 0.00% |